Women with a history of breast cancer tend to have more severe and frequent vasomotor symptoms than the general population. Numerous studies have shown that vasomotor symptoms (VMS) are the most frequent adverse event of adjuvant therapy, and that up to 20% of breast cancer patients consider discontinuing treatment because of these symptoms, despite their benefit in the reduction of recurrence. While hormone replacement therapy (HRT) is regularly used in healthy women to treat VMS, it is contraindicated in patients with history of breast cancer. There are few clinical data on non-pharmacological interventions, and the role of alternative and complementary therapies remains controversial. The review of the literature reveals that these pharmacological agents, serotonin-norepinephrine reuptake inhibitors (SSRIs), selective serotonin reuptake inhibitors (IRSs), antihypertensives and anticon...